Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer by Erselcan, T et al.
Anthracyclines are used extensively in therapy of several types of
human cancer where long-term survival and cure are common,
such as haematological malignancies and paediatric cancers. They
are now increasingly used also in adjuvant therapy of breast 
cancer, because the results of some trials suggest that anthracy-
cline-containing combinations are associated with better survival
than non-anthracycline-containing regimens (Early Breast Cancer
Trialists’ Collaborative Group, 1998). These trials have, however,
only limited follow-up of a few years. Cardiotoxicity is a well-
established side-effect of anthracyclines, and subclinical cardiotox-
icity of adjuvant and other curative therapies might manifest only
several decades after treatment when the myocardial reserves 
start to decrease in old age. This might counterbalance the short-
term absolute survival benefit associated with anthracycline-
containing regimens over CMF (cyclophosphamide, 5-fluorouracil
and methotrexate), which is only about 3% at 5 years of follow-up
according to the meta-analysis (Early Breast Cancer Trialists’
Collaborative Group, 1998). Cardiotoxicity of anthracyclines may
be reduced by low-peak therapies, such as anthracyclines given as
long infusions (Legha et al, 1982). A novel iron-chelating agent,
dexrazoxane, has reduced anthracycline-associated cardiotoxity in
several randomized trials, and apart from one study, it has not
reduced response rates (Green, 1998).
High-dose chemotherapy is used increasingly in therapy of
breast cancer both in the US and Europe (Antman et al, 1997;
Grathwohl et al, 1997). In the USA, breast cancer is the most
common indication for high-dose chemotherapy given with the
support of either bone marrow or peripheral blood stem cell rescue
at present (Antman et al, 1997). It is currently highly controversial
whether high-dose chemotherapy is superior to conventional-dose
chemotherapy either in the adjuvant or the metastatic setting, but
several controlled trials are currently in progress to resolve the
issue. Favourable results have been obtained with adjuvant high-
dose therapy in phase II studies (Peters, 1996), and many breast
cancer patients with a high risk of relapse are now given high-dose
therapy. However, besides its efficacy, the long-term risks of high-
dose therapy are unsettled. Little is known about the subclinical
cardiac toxicity related to high-dose adjuvant therapy, which might
be of great importance for the long-term survivors from cancer.
Endomyocardial biopsy is the most reliable method to diagnose
anthracycline-induced cardiotoxicity. However, a non-invasive
method of indium-111 monoclonal antimyosin antibody scintig-
raphy has been shown to be highly sensitive for detecting cardiac
damage. The method is capable for detecting even small areas of
myocardial damage or necrosis in a variety of diseases (Estorch et
al, 1993; Verna et al, 1995; Astorri et al, 1996; Ballester et al,
1997a, 1997b; Bengel et al, 1997; Schutz et al, 1997). Moreover, it
may be the only non-invasive method currently available for
detection of subclinical myocardial damage.
The aim of the present study was to compare subclinical
myocardial damage caused by three different adjuvant therapies
used in treatment of breast cancer. Two of the regimens contained
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compared on a milligram per milligram basis, but is usually used
in 20–30% larger doses than doxorubin. Patients in one of the
groups evaluated received high-dose therapy with CTCb, which is
one of the most commonly used high-dose regimens, and we
studied also patients who had been treated with a presumably low-
cardiotoxic regimen (cyclophosphamide, methotrexate and fluoro-
uracil CMF) as controls.
PATIENTS AND METHODS
Patients and therapy given
Thirty-six women with histologically proven breast cancer were
entered in the study. None of the participants had any known
previous cardiac disease in history, medication for cardiac disease,
or signs of cardiac dysfunction in the clinical examination. The
renal and hepatic functions were required to be normal. The
staging examinations included mammography, chest X-ray,
isotope bone scan, ultrasound or computerized tomography of the
abdomen and a blood chemistry profile. Patients treated with
anthracyclines had an electrocardiogram recorded before starting
chemotherapy. Both patients who received the high-dose therapy
and those treated with dose-escalated FEC (5-fluorouracil, epiru-
bicin and cyclophosphamide) participated in a randomized trial
carried out by the Scandinavian Breast Cancer Group comparing
dose-escalated FEC to high-dose chemotherapy in high-risk breast
cancer with at least five axillary nodes positive for cancer. The
patients had been subjected to modified radical mastectomy or
breast conserving surgery prior to adjuvant chemotherapy, and
following chemotherapy they received post-operative radio-
therapy to the breast, chest wall and the axilla. The total dose was
50 Gy. In patients treated with mastectomy, radiotherapy was
given to the chest wall with 6–9 MeV electrons and in patients
treated with breast conservation the breast was irradiated with 2
opposed oblique fields to avoid cardiac irradiation. We required
that 6–36 months had elapsed from the last dose of adjuvant
chemotherapy (range 8–36 months). The patients fulfilling these
inclusion criteria were chosen at random for the study from the
patients visiting the Department of Oncology, Helsinki University
Hospital, for follow-up. The study was approved by an Ethical
Committee. A written informed consent was required.
Chemotherapy regimens
Three types of adjuvant chemotherapy were compared. In group I
(dose-escalated FEC, n = 14) the patients received FEC every 3
weeks for nine cycles, supported by granulocyte growth factors
(G-CSF, Filgrastim®). The doses of cyclophosphamide and epiru-
bicin were modified according to the nadir leucocyte and platelet
counts (Bergh et al, 1998). The epirubicin doses ranged from 60 to
120 mg m–2 per cycle (the starting dose was 75 mg m–2), the
cyclophosphamide doses from 600 to 1800 mg m–2 per cycle (the
starting dose was 900 mg m–2), and the 5-fluorouracil dose was
fixed to 600 mg m–2. In group II (high-dose chemotherapy, n = 14)
first two cycles of the standard FEC (5-fluorouracil 600 mg m–2,
epirubicin 60 mg m–2, cyclophosphamide 600 mg m–2) were given
3-weekly, followed by a third FEC cycle with escalated cyclophos-
phamide (1200 mg m–2) with G-CSF for stem cell mobilization,
and finally a cycle of high-dose chemotherapy was given. The
high dose regimen was CTCb, consisting of cyclophosphamide
6000 mg m–2, thiotepa 600 mg m–2 and carboplatin 800 mg m–2 as
a continuous infusion over 4 days, followed by infusion of periph-
eral blood stem cells. No further cycles of FEC were given after
the high-dose therapy. In group III (CMF, n = 8) therapy consisted
of standard intravenous (i.v.) CMF (cyclophosphamide 600 mg
m–2, methotrexate 40 mg m–2, 5-fluorouracil 600 mg m–2) for six
cycles repeated every 3 weeks.
The characteristics of the patients are shown in Table 1. The
groups are well balanced with respect of age and time from the last
dose of chemotherapy. The cardiac absorbed dose from external
radiotherapy was minimal in all patients (median, 1 Gy in all three
groups). Only 11 patients received more than a cumulative dose of
1 Gy to the myocardium (group I, n = 3; group II, n = 5; group III,
n = 3), and the maximum cumulative myocardial dose in any
patient in the series was only 2.5 Gy. Two group I patients, four
group II patients and three group III patients were treated with 2
opposed tangential photon fields after breast conserving surgery,
whereas the rest received electrons to the thoracic wall following
mastectomy. The median cumulative dose of epirubicin was 
734 mg m–2 among patients treated with escalated FEC and 181
mg m–2 in the high-dose group. The median cumulative dose of
cyclophosphamide was slightly higher in group I than in group II
(9189 and 8395 mg m–2 respectively), and clearly less among
patients treated with CMF (3600 mg m–2).
Scintigraphy
Scintigraphy was performed 48 h after an i.v. injection of 0.5 mg
of monoclonal R11D10-Fab-fragments (Centocor, Leiden, The
Netherlands), labelled with 74 MBq of In-111. The diethylenetri-
aminepentaacetic acid (DTPA)-derivative of this antibody frag-
ment was labelled as described in detail elsewhere (Kairemo et al,
1990). Anterior planar chest scans were obtained using a gamma
camera (General Electric, Maxi 500) with a medium energy colli-
mator. A 20% window was centred on both peaks (173 keV and
247 keV) of In-111, and a minimum of 500 000 counts were
collected and stored in a 128 ´ 128 matrix frame. Evaluation of the
scans was made blinded for the treatments given and other clinical
data. The absolute cardiac antimyosin uptake (% ID cm–3) was
calculated using a region of interest (ROI) technique with the aid
of a cardiac phantom. The heart-to-lung ratio (HLR) was deter-
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Table 1 Characteristics of the patients and treatments given
Characteristic Dose-escalated FEC ´ 3 CMF ´ 6
FEC ´ 9 +CTCb
Median age 50 51 48
(range), years (39–59) (36–59) (38–54)
Months since last dose 17 24 17
of chemotherapy (8–30) (8–36) (16–20)
median (range), months
Median cardiac dose 1.0 1.0 1.0
median (range), Gy (1.0–2.5) (1.0–2.5) (1.0–2.5)
Cumulative dose of 734 181 None
epirubicin, median (502–895) (174–183)
(range), mg m–2
Cumulative dose of 9189 8395 3600
cyclophosphamide (5713–10 800) (7829–8670) (3000–3600)
median (range mg m–2)mined by dividing the average counts per pixel in the heart ROI by
the average counts per pixel in the lung ROI. The HLR was used as
a semiquantitative parameter for myocardial damage. A value
larger than 1.58 was considered as pathological based on the data
published earlier by Carrio et al (1993).
Statistical analysis
Comparisons of different groups was done using the non-para-
metric Mann–Whitney U-test. Spearman’s correlation coefficient
was used in assessing correlations between two parameters. All P-
values are two-tailed.
RESULTS
The cardiac antimyosin uptake and HLRs are shown in Table 2. As
expected, the uptake was significantly greater among patients
treated with dose-escalated FEC than the women treated with
CMF (0.014 vs 0.009% ID cm–3, P < 0.05). However, uptake of In-
111 was less also among patients treated with three cycles of FEC
and high-dose chemotherapy than among those given nine cycles
of dose-escalated FEC (P < 0.05), and there was no difference in
the mean cardiac uptake between patients treated with high-dose
chemotherapy and those given CMF (P > 0.1).
Similar results were obtained, when the HLRs were calculated
(Figure 1). The HLRs were large in group I (median 1.98; range
1.36–2.24) as compared to group II (median 1.51; range
1.20–1.82; P < 0.001) or to group III (median 1.44; range
1.15–1.68;  P < 0.001). There was no significant difference in the
HLRs between patients treated with high-dose therapy or CMF.
The HLR was higher than the chosen cut-off level of 1.58 in 13
(93%) out of the 14 patients in group I, six (43%) out of the 14
patients in group II, and in one (13%) of the eight patients in group
III.
The association between the HLRs and the cumulative dose of
epirubicin received is shown in Figure 2. The data fits with a linear
regression model, the higher the epirubicin dose given, the higher
the uptake (R2 = 0.59, P < 0.001). No correlation was found
between the HLRs and the time elapsed since the last dose of
chemotherapy, or between the HLRs and the estimated absorbed
cardiac dose of radiation.
DISCUSSION
In the present study almost all patients treated with dose-escalated
FEC had cardiac antimyosin uptake that was considered as patho-
logical, whereas only one patient treated with i.v. CMF had such
findings. Moreover, the only patient in the dose-escalated FEC
group with a HLR considered as normal had received the lowest
cumulative dose of epirubicin in this group of patients (502 mg
m–2). Interestingly, the cardiac uptake of the patients treated with
three cycles of conventional FEC and high-dose CTCb differed
only marginally from the uptakes measured in patients treated with
CMF, suggesting that both a short course of conventional FEC and
a single course of CTCb are less cardiotoxic as compared with the
dose-escalated FEC. The limited subclinical cardiotoxicity found
among patients treated with high-dose CTCb 8–36 months after
therapy suggests that long-term cardiotoxicity related to alkylating
agents even if given in high single doses may not be of a major
concern, at least in comparison to moderately high peak doses of
epirubicin. However, the clinical consequences of subclinical
cardiotoxicity detected by antimyosin antibody scintigraphy
remain uncertain and may require long-term follow-up of the
patients.
The biological action of the anthracyclines includes inhibition
of the mitochondrial oxidative phosphorylation, DNA and RNA
polymerases and DNA repair enzymes, the metallothionein
synthesis, topoisomerase II and the helicases. Further effects occur
by the production of free radicals, membrane modulation and
endonucleolytic cleavage (Booser and Hortobagyi, 1994).
Epirubicin-induced pathological changes in the human
myocardium are similar to those of doxorubicin, such as dilation
of the sarcoplasmic reticulum, myofibrillar loss and increase in
interstitial fibrosis without inflammatory cells (Torti et al, 1986).
Although the extent of cardiotoxic damage can be most accu-
rately determined by endomyocardial biopsy, the invasive nature
of the method limits its use in clinical practice. Serial left ventric-
ular ejection fraction measurements, although controversial, are
the most widely used method for cardiac monitoring during
chemotherapy administration. In-111 antimyosin monoclonal anti-
body scan is also minimally invasive, and it has been successfully
used in several clinical trials to detect acute doxorubicin cardio-
toxicity (Estorch et al, 1993; Carrio et al, 1993, 1995; Valdes et al,
1994).
Binding of this antibody to intracellular myosin takes place only
after sarcolemmal disruption is present. Only cardiac and skeletal
myosin show high specificity to antimyosin antibody (Kairemo et
al, 1990; Bhattacharya and Lahiri, 1991), and, therefore, also
extracardial lesions may be detected (Kairemo et al, 1996). The
myocardial uptake of In-111 antimyosin monoclonal antibody
correlates well with the pathologic grade of the cell damage 
in myocarditis (Yamada et al, 1990). Moreover, pathologic
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Table 2 Uptake of In-111-labelled antimyosin antibody in patients treated with three different adjuvant
chemotherapy protocols
Characteristic Dose-escalated FEC ´ 3 + CTCb CMF ´ 6
FEC ´ 9
(group I, n = 14) (group II, n = 14) (group III, n = 8)
Cardiac antimyosin uptake (% ID cm–3)
Median 0.014 0.009 0.009
(range) (0.008–0.030) (0.002–0.016) (0.005–0.016)
Heart-to-lung ratio
Median 1.98 1.51 1.44
(range) (1.36–2.24) (1.20–1.82) (1.15–1.68)myocardial antimyosin antibody uptake has been observed long
after the onset of myocardial cell damage. Yamada et al (1992)
demonstrated positive antimyosin uptake in 71% of patients with a
myocardial infarction 1.5–12 months after the incident by In-111-
antimyosin scans.
In the present study the amount of subclinical cardiac damage
paralleled the cumulative epirubicin dose given. As with doxoru-
bicin, congestive heart failure following administration of epiru-
bicin is well documented in the literature (Nielsen et al, 1990;
Lopez et al, 1998). Jensen and collaborators (1996) found severe
chronic cardiac failure in nearly 10% of patients with breast cancer
treated with epirubicin. In their series, cardiac failure developed at
a median of 2.5 months after the last dose of epirubicin. As with
doxorubicin, the incidence of epirubicin-induced cardiac failure is
greatly dependent on the cumulative dose of epirubicin, but it
depends also on other factors, such as the mode of administration
of epirubicin, concomitant medication, presence of previous
cardiac disease, amount of cardiac irradiation and individual and
unrecognized factors. Congestive cardiac failure is rare at cumula-
tive epirubicin doses less than 1000 mg m–2 in patients without
known risk factors for cardiac failure (Jain et al, 1985; Dardir et al,
1989; Nielsen et al, 1990). However, no studies have yet addressed
the clinical significance of subclinical cardiac damage, which may
be a highly relevant issue in the long-term follow-up.
Cyclophosphamide may also be cardiotoxic, and it may add to
the toxicity caused by anthracyclines especially when given in
very high doses (Fraiser et al, 1991). Echocardiographic studies
have found that left ventricular dysfunction occurs in over 50% 
of patients undergoing transplantation, and cyclophosphamide
cardiotoxicity may be a lethal complication of high-dose therapy
(Goldberg et al, 1986; Braverman et al, 1991). However, in the
present series the cumulative dose of cyclophosphamide was
approximately similar in groups I and II, but the extent of subclin-
ical cardiotoxicity differed considerably between the groups,
suggesting that the cumulative dose of cyclophosphamide was not
a major determinant for post-transplantation cardiotoxicity.
Cardiotoxicity of fluorouracil is low, and the differences in the
cumulative doses of fluorouracil are unlikely to explain the present
results. The amount of cardiac irradiation was minimal in all three
groups. Hence, epirubicin is the likely candidate to explain the
increased cardiac uptake of the antimyosin antibody.
We conclude that the majority of patients treated with dose-
escalated epirubicin show increased uptake of In-111-labelled
antimyosin antibody compatible with subclinical cardiotoxicity.
Similar high uptake was not found among patients treated with
three cycles of conventional FEC and high-dose chemotherapy
containing alkylating agents, suggesting that cardiotoxicity of
these treatments is small when assessed a few months to a few
years after treatment as compared with nine cycles of dose-esca-
lated FEC, and may not be substantially greater than that of intra-
venously given CMF. Premature adoption of adjuvant regimens
consisting of high cumulative doses or high peak doses of anthra-
cyclines given without cardioprotective drugs may abrogate the
survival benefits possibly associated with such regimens, and we
recommend that clinical trials with long-term follow-up data are
available before adjuvant regimens using high anthracycline doses
are widely used.
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